Panelists discuss how managing patients with comorbidities requires careful evaluation to distinguish true Group 1 PAH features from underlying cardiac or pulmonary disease, with a more measured ...

Disclosures CHF. 2003;9 (3) 0 Pathogenesis and Classification The pulmonary vasculature is the exclusive target of disease in PPH, although its pathogenesis remains speculative.

Jake Takahashi, who was deferred from Stanford early action, was chosen as one of 40 finalists for the Intel Science Talent Search for his work on the pathogenesis of pulmonary arterial hypertension.

Pulmonary hypertension is a rare, ostensibly incurable, and etiologically diverse disease with an unacceptably high 5-year mortality rate (≈50%), worse than many cancers. Irrespective of pathogenic ...

Pulmonary arterial hypertension (PAH) is a rare but lethal disorder caused by several pathological changes in the pulmonary vasculature. There is endothelial cell dysfunction characterized by ...

Since 1970, deaths from heart attacks have dropped nearly 90%, thanks to life-saving interventions and public health measures ...

In 1970, someone over the age of 65 hospitalized for a heart attack in the United States had about a 60% chance of leaving ...

Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints.

Long-term exposure to particulate matter in patients with pulmonary arterial hypertension increases risk for lung transplantation or death.